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ABSTRACT
Objectives Guidance recommends statin treatment in 
familial hypercholesterolaemia (FH) to achieve at least 
a 50% reduction in low- density lipoprotein cholesterol 
(LDL- C). We assessed statin prescribing rates and LDL- C 
treatment goal attainment among individuals with FH in 
primary care.
Methods Using primary care electronic health records 
from the UK Clinical Practice Research Datalink, we 
identified adults with recorded diagnosis of FH, statin 
treatment and measures of LDL- C prior to (baseline) and 
12 months after initiating statin treatment. The percentage 
change in LDL- C was determined, and then baseline 
and treatment characteristics were assessed by LDL- C 
treatment goal attainment.
Results Of 3064 adults (mean age 50.8 years) with 
recorded diagnosis of FH and repeat LDL- C measures, 
50% reduction in LDL- C from baseline was attained in 
895 individuals (29.2%) in 12 months. Compared with 
those who did not attain this goal, these people were 
predominantly women; they were older at time of FH 
diagnosis (53.4 years vs 49.7 years) and first statin 
treatment (53.2 years vs 49.2 years) and had higher 
pretreatment total cholesterol (8.20 (SD 1.38) mmol/L vs 
7.57 (SD 1.39) mmol/L) and pretreatment LDL- C (5.83 
(SD 1.36) mmol/L vs 5.25 (SD 1.40) mmol/L). A higher 
proportion of individuals who attained the treatment goal 
was prescribed high- potency and medium- potency statins 
(24.3% and 71.7% vs 20.2% and 69.3%, respectively).
Conclusions Less than a third of individuals on statin 
treatment for FH in the community achieve recommended 
reductions in LDL- C. Greater awareness and optimisation 
of treatment for FH using higher- potency statins are 
needed.
INTRODUCTION
Familial hypercholesterolaemia (FH) is a 
genetic condition that causes lifelong elevated 
low- density lipoprotein cholesterol (LDL- C) 
and is associated with significant cardiovas-
cular morbidity and mortality.1 2 Reducing 
the LDL- C level is one of the primary goals 
in managing individuals with FH, and treat-
ment with lipid- lowering drugs such as statins 
reduces LDL- C burden and consequently the 
cardiovascular disease (CVD) and mortality 
risk associated with FH.3 4
In the treatment of adults with FH, the 
UK National Institute for Health and Care 
Excellence (NICE) guidelines recommend 
at least a 50% reduction in serum LDL- C 
concentration from the baseline measure-
ment.5 Recent guidelines from the European 
Society of Cardiology/European Atheroscle-
rosis Society (ESC/EAS) recommend in addi-
tion to the LDL- C reduction of ≥50% from 
baseline, LDL- C treatment targets of <1.8 
mmol/L in adults with FH, or <1.4 mmol/L 
in adults with FH and CVD or other major 
risk factors.6
The degree of LDL- C reduction varies with 
statins of different potencies.7 Also, there is 
interindividual variation in LDL- C reduction 
Key questions
What is already known about this subject?
 ► The use of statins to reducing low- density lipopro-
tein cholesterol (LDL- C) burden is one of the cen-
tral goals of familial hypercholesterolaemia (FH) 
management, and national and international guid-
ance recommend that treatment should achieve 
at least a 50% reduction in LDL- C from baseline 
measurement.
What does this study add?
 ► This study provides novel evidence of suboptimal 
LDL- C reduction in individuals with FH who are be-
ing treated with statins, such that less than 40% of 
patients are treated with high- intensity statins at 12 
months, and two- thirds of patients initiated on statin 
treatment fail to attain the recommended treatment 
target.
How might this impact on clinical practice?
 ► These findings highlight the need for greater aware-
ness of FH and the need to optimally manage these 
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with statin therapy,8 which may partly be due to poor medi-
cation compliance9 or genetic factors.10 In the general 
population, it has been shown that over half of patients 
commenced on statin therapy for primary prevention 
of CVD do not attain optimal LDL- C reduction after 
24 months of treatment.11 There is limited evidence of 
the magnitude of LDL- C reduction after initiation of 
statins in individuals with FH, in real- world community 
settings. This study explored statin prescribing patterns 
in individuals with FH in primary care and then assessed 
LDL- C reduction and treatment goal attainment in these 
patients following initiation of statins.
METHODS
Data source
The UK Clinical Practice Research Datalink (CPRD) is 
a large electronic database of anonymised longitudinal 
routine primary care health records. The database has 
coverage of approximately 15% of the UK population, 
and patients are representative of the UK population 
in terms of age and sex.12 Individuals’ primary care 
records in CPRD were linked with their secondary care 
records (hospital episode statistics) and death registra-
tion records from the Office for National Statistics. Data 
access and ethical approval for the study were granted 
by the CPRD Independent Scientific Advisory Committee 
(protocol number 20_093) in June 2020.
Study population
We identified all individuals aged 18 years or older who 
had a coded clinical diagnosis of FH in their primary 
care record, a record of treatment with statins of known 
potency, a measure of LDL- C prior to commencing statin 
treatment and a repeat LDL- C measure 12 months after 
initiating statin treatment. Patients were eligible for 
inclusion in the study if they had been registered in their 
general practice for at least 1 year and had no records 
of pre- existing CVD before being commenced on statins.
LDL-C measures and other covariates
The baseline LDL- C measure was defined as the most 
recent LDL- C in patients’ records in the 12- month 
period before the first treatment with statins. LDL- C at 12 
months was the last measure recorded after 6 months and 
within the 12 months after initiating statin treatment.
Patient characteristics collected at baseline include age; 
sex; ethnicity; history of alcohol misuse; smoking status; 
physical activity level; comorbidities including atrial 
fibrillation, hypertension, type 2 diabetes, overweight/
obesity and chronic kidney disease; and use of medica-
tion that could secondarily cause hyperlipidaemia such 
as corticosteroids and antipsychotics. The categorising 
of statin potency (high, medium or low intensity) takes 
account of the estimated percentage reduction in LDL- C 
expected using varying doses of different statins.13 
Low- intensity statins produce an LDL- C reduction of 
20%–30%, medium- intensity statins produce a reduction 
of 31%–40% and high- intensity statins produce an LDL- C 
reduction greater than 40%7
Outcome ascertainment
Patients were followed up from the first date of prescrip-
tion of a statin with known potency. Baseline lipid meas-
ures (LDL- C) and repeated LDL- C measure at 12 months 
were used to determine the percentage change in LDL- C 
during the period of follow- up. Based on the NICE FH 
treatment guideline recommendation that states that 
statin treatment in individuals with FH should aim to 
achieve at least a 50% reduction in LDL- C concentration 
from baseline measurement,14 patients were classified 
as goal attainers or non–goal attainers, depending on 
whether they achieved the 50% or greater reduction in 
LDL- C or not, respectively.
Statistical analyses
In the study cohort of individuals with FH, serum concen-
trations of lipids such as total cholesterol, LDL- C, high- 
density lipoprotein cholesterol and triglycerides, as well 
as types and potency of lipid- lowering treatment, were 
assessed at baseline, 12 months and 24 months. Change 
in LDL- C at 12 months was calculated by dividing the 
difference between the LDL- C at baseline and LDL- C 
at 12 months, by the baseline LDL- C concentration, 
and this was expressed as a percentage. As previously 
described, individuals were categorised as goal attainers 
or non–goal attainers, depending on their percentage 
change in LDL- C at 12 months. Baseline characteristics 
including the clinical profile and treatment character-
istics were explored in the cohort who attained the 50% 
LDL- C reduction treatment goal and those who did 
not. χ2 test of significance, t- tests and Mann- Whitney U 
tests were used to assess differences in categorical and 
continuous variables between LDL- C goal attainers and 
non–goal attainers, depending on the distribution of 
the variables. After determining the change in LDL- C 
at 12 months, further analyses determined change in 
LDL- C at 24 months. LDL- C at 24 months was defined 
as the last LDL- C measure after 12 months but within 
the 24- month period after initiating statin treatment. 
We further assessed attainment of at least a 40% reduc-
tion in LDL- C, which is the NICE- recommended target 
for the general population of non- FH individuals who 
are initiated on statins for the primary prevention of 
CVD.15
Following primary analyses conducted on all indi-
viduals with FH diagnosis in primary care, a sensitivity 
analysis was done on the subset of individuals who had 
a diagnosis of FH as well as baseline total cholesterol of 
7.5 mmol/L or greater, which is the FH total cholesterol 
diagnostic threshold.2 Further sensitivity analysis also 
assessed treatment goal attainment with respect to the 
ESC/EAS guidelines.6 Statistical significance was defined 
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RESULTS
A total of 3064 adults had clinical diagnostic codes for 
FH, records of statin with known potency at baseline, 
LDL- C measures at baseline and 12 months and no 
history of CVD prior to being initiated on statins, between 
December 1988 and August 2020. Statin treatment and 
lipid profile of these individuals at baseline, as well as 12 
and 24 months after starting treatment with statins, are 
shown in table 1.
Over the period of follow- up, the proportion of indi-
viduals prescribed with low- potency statins reduced 
from baseline to 24 months (8.6% at baseline, 6.6% at 
12 months and 5.7% at 24 months), while the propor-
tion prescribed with high- potency statins increased over 
time, from 21.4% at baseline, 36.2% at 12 months and 
39.3% at 24 months. Compared with the baseline LDL- C 
value, there was a mean reduction in LDL- C of 36.3% at 
12 months (5.42 mmol/L vs 3.45 mmol/L) and 39.5% at 
24 months (5.42 mmol/L vs 3.28 mmol/L).
Prior to restricting our study sample to the 3064 eligible 
adults with FH (who were treated with statins, with no 
CVD prior to statin initiation and with LDL- C measures 
at baseline and 12 months), we assessed the pattern of 
lipid- lowering treatment prescribing 8234 adults with FH 
and no prior CVD. Findings showed an increase in the 
prescribing of non- statin lipid- lowering treatments such 
as ezetimibe (monotherapy or prescribed in combination 
with statins) (0.05% at baseline, 3.2% at 12 months and 
4.2% at 24 months) and fibrates (0% at baseline, 1.1% at 
12 months and 1.4% at 24 months) (online supplemental 
table 1).
LDL-C treatment goal attainment
Of the 3064 individuals in our FH study cohort, 895 
(29.2%) achieved a 50% or greater reduction in LDL- C 
concentration from the baseline measure, 12 months 
after statin initiation. Repeat LDL- C measures were avail-
able for 1662 individuals at 24 months, and 558 (33.6%) 
achieved a 50% or greater reduction in LDL- C from base-
line (table 1).
A 40% reduction in LDC- C from baseline, which is the 
NICE- recommended goal for the general population 
of non- FH individuals initiated on statins for primary 
prevention of CVD, was achieved at 12 months by 51% of 
the FH cohort and at 24 months by 56.3% of the cohort.
Characteristics of individuals by LDL treatment goal 
attainment at 12 months
Table 2 shows the baseline and lipid- lowering treatment 
characteristics of individuals, by LDL treatment goal 
attainment at 12 months. Compared with individuals 
who did not attain the LDL- C treatment goal of 50% or 
greater, a significantly higher proportion of those who 
attained the goal was women. Individuals who attained the 
treatment goal were of older age at time of FH diagnosis 
(53.4 years vs 49.7 years) and at time of first statin treat-
ment (53.2 years vs 49.2 years), and they had significantly 
higher mean pretreatment total cholesterol (8.20 (SD 
Table 1 Lipid profile, statin treatment and treatment goal attainment in adults with FH in UK primary care (n=3064)
Characteristics Unit Baseline 12 months 24 months
Individuals’ lipid profile
  Total cholesterol (mmol/L) Mean (SD) 7.76 (1.42) 5.56 (1.40) 5.42 (1.30)
  LDL- cholesterol (mmol/L) Mean (SD) 5.42 (1.41) 3.45 (1.37) 3.28 (1.23)
  HDL- cholesterol (mmol/L) Mean (SD) 1.50 (0.49) 1.49 (0.47) 1.51 (0.49)
  Triglycerides (mmol/L) Median (IQR) 1.70 (1.20–2.47) 1.40 (1.00–2.00) 1.32 (0.93–2.00)
Potency of prescribed statins*
  (n=3064) (n=2142) (n=1940)
  Low n (%) 264 (8.62) 142 (6.63) 111 (5.72)
  Medium 2145 (70.01) 1225 (57.19) 1067 (55.00)
  High 655 (21.38) 775 (36.18) 762 (39.28)
LDL- C reduction at follow- up
  FH treatment goal attainment (n=3064) (n=1662)
   Attained ≥50% reduction n (%) 895 (29.21) 558 (33.57)
   Non- attainment of 50% reduction 2169 (70.79) 1104 (66.43)
  General population goal attainment (n=3064) (n=1662)
   Attained ≥40% reduction n (%) 1566 (51.11) 935 (56.26)
   Non- attainment of 40% reduction 1498 (48.89) 727 (43.74)
*Statin potency at 12 months and 24 months was reported in individuals with LDL- C records at baseline and 12 months, as well as statin 
potency records at 12 and 24 months, respectively. Total number and percentage n (%) for potency were based only on those with potency 
records, with the exclusion of missing records.
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Table 2 Baseline and treatment characteristics of individuals, by LDL- cholesterol treatment goal attainment at 12 months 
(n=3064)
Patient or treatment 
characteristics Unit
Total N (%)
LDL- C goal attained 
N (%)
LDL- C goal not 
attained N (%)
P value3064 (100) 895 (29.21) 2169 (70.79)
Women N (%) 1873 (61.13) 590 (65.92) 1283 (59.15) <0.001
Ethnicity N (%)
  White 1610 (91.74) 452 (92.24) 1158 (91.54)
  Asian/British Asian 74 (4.22) 10 (4.08) 54 (4.27) 0.366
  Black/Black British 27 (1.54) 7 (1.43) 20 (1.58)
  Mixed 10 (0.57) 0 10 (0.79)
  Others 34 (1.94) 11 (2.24) 23 (1.83)
Age (years) at FH diagnosis Mean (SD) 50.79 (13.13) 53.44 (12.60) 49.71 (13.20) <0.001
Age (years) at first statin Mean (SD) 50.33 (12.83) 53.18 (12.48) 49.16 (12.80) <0.001
Pretreatment total cholesterol 
(mmol/L)
Mean (SD) 7.76 (1.42) 8.20 (1.38) 7.57 (1.39) <0.001
Pretreatment LDL- C (mmol/L) Mean (SD) 5.42 (1.41) 5.83 (1.36) 5.25 (1.40) <0.001
Post- treatment LDL- C (12 months) 
(mmol/L)
Mean (SD) 3.45 (1.37) 2.43 (0.63) 3.88 (1.37) <0.001
Pretreatment HDL- C (mmol/L) Mean (SD) 1.50 (0.49) 1.59 (0.57) 1.46 (0.45) <0.001
Pretreatment triglycerides (mmol/L) Mean (SD) 1.70 (1.20–2.47) 1.70 (1.20–2.47) 1.70 (1.20–2.46) 0.5087
Statin potency at baseline N (%)
  Low 264 (8.62) 36 (4.02) 225 (10.51)
  Medium 2145 (70.01) 642 (71.73) 1503 (69.29) <0.001
  High 655 (21.38) 217 (24.25) 438 (20.19)
Statin potency at 6 months N (%)
  Low 188 (6.14) 26 (2.91) 162 (7.47)
  Medium 1571 (51.27) 485 (54.19) 1086 (50.07) <0.0001
  High 772 (25.20) 298 (33.30) 474 (21.85)
  Missing record 533 (17.40) 86 (9.61) 447 (20.61)
Statin potency at 12 months N (%)
  Low 142 (4.63) 17 (1.90) 125 (5.76) <0.0001
  Medium 1225 (39.98) 426 (47.60) 799 (36.84)
  High 775 (25.29) 301 (33.63) 474 (21.85)
  Missing record 922 (30.09) 151 (16.87) 771 (35.55)
Cigarette smoking status at baseline N (%) n=2126 n=615 n=1511
  Current 628 (29.54) 160 (26.02) 468 (30.97) <0.001
  Ex 461 (21.68) 135 (21.95) 326 (21.58)
  Never 1037 (48.78) 320 (52.03) 717 (47.45)
Alcohol misuse (yes) N (%) 35 (1.14) 14 (1.56) 21 (0.97) 0.158
Atrial fibrillation N (%) 18 (0.59) 8 (0.89) 10 (0.46) 0.154
Chronic kidney disease N (%) 40 (1.31) 19 (2.12) 21 (0.97) 0.01
Hypertension N (%) 406 (13.25) 120 (13.41) 286 (13.19) 0.869
Type 2 diabetes N (%) 45 (1.47) 15 (1.68) 30 (1.38) 0.54
Obesity/overweight N (%) 320 (10.44) 97 (10.84) 223 (10.28) 0.647
Physical activity level N (%) n=331 n=94 n=237
  Extremely inactive 23 (6.95) 7 (7.45) 16 (6.75) 0.54
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1.38) mmol/L vs 7.57 (SD 1.39) mmol/L) and pretreat-
ment LDL- C (5.83 (SD 1.36) mmol/L vs 5.25 (SD 1.40) 
mmol/L) than those who did not attain the treatment 
goal. Overall, the proportion of individuals treated with 
low- intensity and medium- intensity statins reduced, while 
the proportion of prescribed with high- intensity statins 
increased from baseline to 12 months. Significantly more 
people who attained the LDL- C treatment goal were 
treated with medium- intensity and high- intensity statins 
than those who did not attain the treatment goal, at base-
line (71.7% and 24.3% vs 69.3% and 20.2%, respectively), 
6 months (54.2% and 33.3% vs 50.1% and 21.9%, respec-
tively) and 12 months (47.6% and 33.6% vs 36.8% and 
21.9%, respectively) after statin initiation (table 2 and 
figure 1). Compared with individuals who attained the 
treatment goal, significantly higher proportions of those 
who did not attain the treatment goal were smokers at 
the time of their first statin treatment (31.0% vs 26.0%). 
There were no significant differences in ethnicity, mean 
pretreatment triglycerides, alcohol consumption and 
prevalence of comorbidities such as atrial fibrillation, 
hypertension, type 2 diabetes, obesity and physical activity 
levels between those who attained a ≥50% LDL- C target 
and those who did not. The prevalence of chronic kidney 
disease was higher in those who attained the treatment 
goal compared with those who did not (2.1% vs 1.0%), 
and more people who attained the treatment goal were 
on antipsychotics and corticosteroids than in those who 
did attain the treatment goal.
Patient or treatment 
characteristics Unit
Total N (%)
LDL- C goal attained 
N (%)
LDL- C goal not 
attained N (%)
P value3064 (100) 895 (29.21) 2169 (70.79)
  Moderately active 271 (81.87) 76 (80.85) 195 (82.28)
  Extremely active 8 (2.42) 4 (4.26) 4 (1.69)
Use of other medications N (%)
  Antipsychotics 418 (13.64) 148 (16.54) 270 (12.45) 0.003
  Corticosteroids 292 (9.53) 108 (12.07) 184 (8.48) 0.002
FH, familial hypercholesterolaemia; HDL, high- density lipoprotein; LDL, low- density lipoprotein.
Table 2 Continued
Figure 1 Prescribing of low- potency, medium- potency and high- potency statins among LDL- C goal attainers and non–goal 
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Sensitivity analyses
Table 3 shows the result of analyses restricted to 1805 indi-
viduals who had clinical FH diagnoses and baseline total 
cholesterol of 7.5 mmol/L or greater. Higher propor-
tions of these individuals were treated with high- potency 
statins at baseline and 12 and 24 months, compared 
with the entire study cohort. Compared with the LDL- C 
concentration at baseline, there was a mean reduction 
in LDL- C of 39.8% at 12 months (6.16 mmol/L vs 3.71 
mmol/L) and 43.0% at 24 months (6.16 mmol/L vs 3.51 
mmol/L), which were greater than reductions observed 
in the entire cohort. Also, compared with the entire study 
cohort, a greater proportion of these individuals attained 
the NICE guideline–recommended LDL- C reduction of 
50% or greater at 12 months (36.0% vs 29.2%) and 24 
months (43.1% vs 33.6%).
Lastly, assessment of the LDL- C treatment goal attain-
ment with respect to the ESC/EAS guidelines showed 
that only 4.5% of the study cohort achieved the goal of 
50% LDL- C reduction and LDL- C <1.8 mmol/L (online 
supplemental table 2). Further restrictions to the subset 
of individuals with clinical FH diagnoses and a diagnostic 
threshold of total cholesterol ≥7.5 mmol/L did not 
demonstrate an increase in the proportions who attained 
the ESC/EAS treatment goals.
DISCUSSION
In this large prospective cohort of adults with FH, the 
NICE- recommended treatment goal of at least a 50% 
reduction in LDL- C from baseline was achieved in less 
than a third of individuals treated with statins. The 
observed mean reduction in LDL- C from baseline was 
36.3% at 12 months and 39.5% at 24 months following 
the initiation of statin therapy. Compared with those 
who did not achieve the treatment target, individuals 
who achieved the treatment target of ≥50% reduction 
in LDL- C from baseline were predominantly women, of 
older age at time of FH diagnosis and on initiation of 
statin treatment; they had more severe mean pretreat-
ment LDL- hypercholesterolaemia, and significantly 
higher proportions of them was treated with high- potency 
statins at baseline and over the 12- month period after 
the initiation of statins. Individuals with FH diagnoses, 
who additionally had baseline LDL- C levels at or above 
the FH diagnostic threshold of 7.5 mmol/L, had greater 
12- month and 24- month reductions in LDL- C after initi-
ating statins, and a higher proportion of them attained 
the NICE guideline LDL- C treatment goal at 12 and 24 
months compared with the entire cohort.
Strengths and limitations
To our knowledge, this is the first study to assess and 
quantify LDL- C reduction associated with statin treat-
ment in individuals with FH in primary care. By using 
pseudonymised but comprehensively coded electronic 
primary care health records from a quality- assured and 
highly representative database,12 we were able to ascer-
tain repeated measures of LDC- C and robustly charac-
terise these individuals using a large sample size and a 
longitudinal study design. The study design minimised 
selection, recall and respondent bias.
We recognise certain limitations. As with all primary 
care electronic health records, the recording of clinical 
diagnosis relies on the accurate and complete recording 
by the general practitioner (GP) during routine consul-
tations.16 17 While we acknowledge the potential for FH 
misclassification in some individuals with hypercholes-
terolaemia due to secondary causes, there were no signifi-
cant differences in the prevalence of comorbid conditions 
between those who attained and those who did not attain 
the LDL- C treatment goal, and thus, there is no reason 
to believe differential effects of such misclassification 
Table 3 Lipid profile at baseline, lipid- lowering treatment and treatment goal attainment, in sensitivity analyses restricted to 
adults with FH diagnosis and baseline total cholesterol ≥7.5 mmo/L (n=1805 at baseline)
Baseline 12 months 24 months
Total cholesterol (mmol/L) Mean (SD) 8.62 (1.09) 5.87 (1.47) 5.68 (1.33)
LDL- cholesterol (mmol/L) Mean (SD) 6.16 (1.25) 3.71 (1.45) 3.51 (1.29)
HDL- cholesterol (mmol/L) Mean (SD) 1.53 (0.49) 1.52 (0.48) 1.53 (0.46)
Triglycerides (mmol/L) Median (IQR) 1.80 (1.29–2.65) 1.40 (1.00–2.10) 1.39 (1.00–2.00)
Potency of prescribed statins* N (%) (n=1805) (n=1299) (n=1172)
  Low 144 (7.98) 84 (6.47) 56 (4.78)
  Medium 1231 (68.20) 668 (51.42) 572 (48.81)
  High 430 (23.82) 547 (42.11) 544 (46.42)
LDL- C reduction at time of follow- up N (%) (n=1805) (n=982)
  Attained 50% reduction 649 (35.96) 423 (43.08)
  Non- attained 50% reduction 1156 (64.04) 559 (56.92)
*Statin potency at 12 months and 24 months was reported in individuals with records of LDL- C at 12 months, as well as records of statin 
potency at 12 and 24 months, respectively.
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between the groups. It was not possible to determine 
whether recorded FH diagnoses were made following 
clinical assessment of FH phenotype or specialist assess-
ment including genetic testing in secondary care or both, 
because there are currently no distinct codes for these 
in clinical systems. As there was no data on FH genetic 
mutation, it was not possible to assess whether there was 
an association between the various FH genetic muta-
tion types and LDL- C treatment goal attainment. Lastly, 
although we explored individuals’ sociodemographic 
and clinical characteristics in relation to their LDL- C goal 
attainment or non- attainment status, we did not have data 
on some of the factors that may be associated with treat-
ment goal attainment such as side effects to statin treat-
ment, non- adherence to treatment and dietary intake, 
and so, we were unable to explore these in our FH study 
cohort. Despite the above limitations, findings from our 
study reflect a pragmatic evaluation of LDL- C treatment 
goal attainment associated with statin therapy in primary 
care patients with FH.
Comparison with previous literature
This is the first study to evaluate LDL- C response to statin 
treatment in primary care patients with FH. Suboptimal 
response to statins had previously been demonstrated in 
over half of the general population of people initiated 
on statins for primary prevention.11 Similarly, findings 
from the EURO ASPIRE V Survey in 78 centres from 
16 European countries found that the recommended 
LDL- C target was achieved in less than half of high–
CVD risk individuals on lipid- lowering medication.18 In 
the FH population, previous studies of lipid- lowering 
therapy have primarily evaluated treatments among 
patients in lipid clinics or specialist registers,19–21 while 
clinical trials have assessed LDL- C reduction associated 
with treatment using more specialised lipid- lowering 
agents such as proprotein convertase subtilisin/kexin 
type 9.22 23 While it had previously been shown that less 
than 50% of the general population who was prescribed 
statins for primary CVD prevention achieved a 40% or 
greater reduction in LDL- C within 24 months, our study 
of the FH population found that 51.1% of individuals at 
1 year and 56.3% of individuals at 2 years achieved this 
general population treatment target. This suggests that 
although individuals with FH may be treated better with 
statins than the general population, their lipid- lowering 
management is not optimal to the level recommended 
in the FH guidelines. The importance of intensive GP 
management of FH has been demonstrated in a study by 
Brett et al, which showed that implementing a pragmatic 
intervention plan by GPs, with the inclusion of statin/
ezetimibe medication±lifestyle advice, resulted in signif-
icant reduction in LDL- C levels.24
While there is no clear explanation for the variation in 
LDL- C reduction in our study population, we hypothesise 
that this may be partly explained by the significant differ-
ences in baseline and treatment characteristics between 
individuals who attained the LDL- C treatment goal and 
those who did not. Perhaps older adults and those with 
higher LDL- C at baseline are more likely to be prescribed 
higher- intensity statins due to their perceived increased 
risk of CVD, which consequently results in better LDL- C 
treatment outcomes.
There were no significant differences in alcohol 
consumption or the reported level of physical activity 
between statin treatment goal attainers and non- attainers, 
but cigarette smoke exposure was higher in those who 
failed to attain the LDL- C treatment goal. Although there 
is no clear evidence that smoking increases the levels of 
LDL- C,25 exposure to cigarette smoke is likely to further 
increase CVD risk in these individuals who fail to attain 
the LDL- C treatment goal.
Clinical implications and conclusion
This study provides novel knowledge of suboptimal 
LDL- C reduction in individuals with FH who are being 
treated with statins. With less than 40% of patients being 
treated with high- intensity statins and lack of attainment 
of the ≥50% LDL- C- lowering treatment goal in two- thirds 
of patients initiated on statin treatment, findings from 
this study highlight significant gaps in the FH patient 
management. Applying multifaceted approach by identi-
fying the barriers to evidence- based FH patient care and 
using a strategic means to tailor effective interventions 
to modifiable barriers at the patient level, physician level 
and health system level are likely to improve implementa-
tion of evidence- based FH patient care and outcomes.26 27 
Emphasis on lifestyle and dietary modification is needed 
to manage raised LDL- C and reduce CVD risk in individ-
uals with FH. Intensive LDL- C lowering has clear bene-
fits in CVD risk reduction,28 29 so it is essential that these 
individuals in primary care are optimally managed and 
intensively monitored. Raising greater awareness of FH, 
in particular of the need for use of higher- potency statins, 
is needed in this setting.
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Supplementary table 1.  Lipid-lowering treatment among individuals with FH in UK Primary 
Care (n=8,234) * 
 
 
 Baseline 12 months 24 months 
Type of lipid-lowering treatment 
Statins 
Ezetimibe + Statins 
Fibrates 





























Supplementary table 2. Attainment of European Society of Cardiology/ European 
Atherosclerosis Society (ESC/EAS) guideline of 50% LDL-C reduction and LDL-C <1.8mmol/L 
EAS treatment goal attainment in study population  12 months 24 months 
Goal attainment in entire study cohort 
Attained 50% LDL-C & LDL-C <1.8mmol/l 









Goal attainment in FH cohort with baseline LDL>=7.5 
Attained 50% LDL-C & LDL-C <1.8mmol/l 
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